Clinical trials: Primary Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Amyotrophic Lateral Sclerosis, Respiratory Muscle Weakness
ALS and Airway Clearance (ALSAC) Therapy
Patients will receive one of three respiratory therapy interventions for airway clearance assistance: 1) High frequency chest wall oscillation (HFCWO) and mechanical insufflation/exsufflation (MIE), 2) HFCWO or 3) MIE.
- Trial name
- ALSAC (NCT04947436)
- Testing
- High Frequency Chest Wall Oscillation, Mechanical insufflation/exsufflation
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Amyotrophic Lateral Sclerosis (ALS)
Magnetic Resonance Imaging (MRI) in Amyotrophic Lateral Sclerosis (ALS)
This is a pilot study to identify the degree of grey and white matter involvement in patients with Amyotrophic Lateral Sclerosis (ALS) utilizing non-invasive techniques.
- Trial name
- NCT01945853
- Testing
- 7 Tesla MRI
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Amyotrophic Lateral Sclerosis
Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
The purpose of the assay is to assess the safety and the efficacy of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, as compared to placebo, assessed by the 18-month…
- Trial name
- MITOTARGET (NCT00868166)
- Testing
- Olesoxime, Riluzole
- Where
- 15 sites in Belgium, France and 3 more
- Volunteers
- 512 people
- Sponsor
- Hoffmann-La Roche
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis
Pilot, phase II, prospective, open-label, uncontrolled study of plasma exchange with 5% albumin in 10 subjects having a definite, possible, or probable diagnosis of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT02479802
- Testing
- Albumin
- Where
- Spain
- Volunteers
- 13 people
- Sponsor
- Instituto Grifols, S.A.
Amyotrophic Lateral Sclerosis, ALS
Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)
The goal of this study is to evaluate the safety and feasibility of IVIg administration in conjunction with primary motor cortex BBB opening using the Next Generation Dome Helmet (NGDH) FUS in adult participants with ALS.
- Trial name
- ALSFUS003 (NCT07193953)
- Testing
- Next Generation Dome Helmet Focused Ultrasound, Intravenous immunoglobulin (IVIG), 10% solution for infusion, Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Sunnybrook Health Sciences Centre
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Cyclophosphamide in Amyotrophic Lateral Sclerosis
The goal of this clinical trial is to learn whether cyclophosphamide (CTX) combined with standard treatment can slow disease progression in adults with amyotrophic lateral sclerosis (ALS).
- Trial name
- CORTEX-ALS (NCT07834450)
- Testing
- Cyclophosphamide, Riluzole
- Volunteers
- 60 people
- Sponsor
- Huashan Hospital
Amyotrophic Lateral Sclerosis
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
The aim of this project is to analyze the macrophage transcriptome and protein markers of Amyotrophic Lateral Sclerosis (ALS) patients compared to controls (non-affected individuals, patients with other motor impairments) and…
- Trial name
- Mac2ALS (NCT04816227)
- Where
- France
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Amyotrophic Lateral Sclerosis
Registration Study of Amyotrophic Lateral Sclerosis (ALS) in Mainland China
A multi-center registration study of natural history and clinical characteristics of ALS in mainland China
- Trial name
- ChALSR (NCT04328675)
- Where
- China
- Volunteers
- 4,752 people
- Sponsor
- Peking University Third Hospital
Amyotrophic Lateral Sclerosis, Bulbar Disease
Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis
PET imaging of activated microglia offers a tool of investigation of a range of brain diseases where neuroinflammation is a component. Amyotrophic lateral sclerosis is the most frequent motoneuronal disease in adult.
- Conditions
- Amyotrophic Lateral Sclerosis, Bulbar Disease, Spinal Disease
- Trial name
- NCT00563537
- Testing
- 18F-X PET SCAN
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Amyotrophic Lateral Sclerosis
A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis
The purpose of this study is to determine determine the safety of intraspinal delivery of mesenchymal stem cells (MSCs) to the cerebral spinal fluid of patients with Amyotrophic Lateral Sclerosis (ALS) using a dose-escalation…
- Trial name
- NCT01609283
- Testing
- autologous mesenchymal stem cells
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Amyotrophic Lateral Sclerosis, ALS
MRI Biomarkers in ALS
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression.
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Motor Neuron Diseases
- Trial name
- NCT02405182
- Testing
- Magnetic Resonance Imaging
- Where
- 6 sites in Canada
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Amyotrophic Lateral Sclerosis, ALS
Open Label Extension Study of AMX0035 in Patients With ALS
This extension study, in which all participants received active treatment (AMX0035), was designed to assess the longer-term safety and therapeutic potential of AMX0035 for participants who have completed the Main Study (AMX3500…
- Trial name
- CENTAUR-OLE (NCT03488524)
- Testing
- AMX0035
- Where
- 24 sites in United States
- Volunteers
- 90 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Amyotrophic Lateral Sclerosis
Open Label Extension of TUDCA-ALS Study
This study will provide extended access to patients and assess longer-term outcomes on patients who have completed the TUDCA-ALS study.
- Trial name
- TUDCA-ALS OLE (NCT05753852)
- Testing
- Tauroursodeoxycholic Acid
- Where
- 23 sites in Belgium, France and 5 more
- Volunteers
- 184 people
- Sponsor
- Humanitas Mirasole SpA
Amyotrophic Lateral Sclerosis
A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS
The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
- Trial name
- NCT05039099
- Testing
- AP-101
- Where
- 13 sites in United States, Belgium and 4 more
- Volunteers
- 73 people
- Sponsor
- AL-S Pharma
Amyotrophic Lateral Sclerosis
Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)
This is a global multicenter study designed to evaluate the safety and clinical effects of 4 oral doses of TCH346 (1.0, 2.5, 7.5, and 15 mg) compared to placebo in patients with mild or mild to moderate stages of ALS.
- Trial name
- NCT00072709
- Testing
- TCH346
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 551 people
- Sponsor
- Novartis Pharmaceuticals
ALS, Amyotrophic Lateral Sclerosis
A Study to Explore the Role of Gut Flora in ALS
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding ALS
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Motor Neuron Disease
- Trial name
- NCT04150809
- Testing
- No intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Amyotrophic Lateral Sclerosis
Phase 3 Study of Dexpramipexole in ALS
The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- EMPOWER (NCT01281189)
- Testing
- Dexpramipexole
- Where
- 82 sites in United States, Australia and 9 more
- Volunteers
- 942 people
- Sponsor
- Knopp Biosciences
Amyotrophic Lateral Sclerosis
Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders
The purpose of this study is to collect CSF and blood samples that can be used in future research studies to identify potential biomarkers in blood and cerebrospinal fluid (CSF) collected in Amyotrophic Lateral Sclerosis (ALS)…
- Trial name
- NCT05116943
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Amyotrophic Lateral Sclerosis
Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)
The investigators want to test feasibility of a structured program of telesurveillance and home cough assistance for ALS patients.
- Trial name
- NCT00613899
- Testing
- telesurveillance
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione Salvatore Maugeri